

Romain Palich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7203500/publications.pdf>

Version: 2024-02-01

27
papers

607
citations

1040056

9
h-index

610901

24
g-index

28
all docs

28
docs citations

28
times ranked

1156
citing authors

#	ARTICLE	IF	CITATIONS
1	Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. <i>PLoS Medicine</i> , 2016, 13, e1001967.	8.4	382
2	Hepatitis C virus incidence in HIV-infected and in preexposure prophylaxis (PrEP)-using men having sex with men. <i>Liver International</i> , 2018, 38, 1736-1740.	3.9	57
3	Ebola virus RNA detection on fomites in close proximity to confirmed Ebola patients; N'Zerekore, Guinea, 2015. <i>PLoS ONE</i> , 2017, 12, e0177350.	2.5	19
4	A 6-Year-Old Child with Severe Ebola Virus Disease: Laboratory-Guided Clinical Care in an Ebola Treatment Center in Guinea. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004393.	3.0	18
5	Recurrence and Occurrence of Kaposi's Sarcoma in Patients Living With Human Immunodeficiency Virus (HIV) and on Antiretroviral Therapy, Despite Suppressed HIV Viremia. <i>Clinical Infectious Diseases</i> , 2020, 70, 2435-2438.	5.8	17
6	Prevalence of genotypic baseline risk factors for cabotegravir+rilpivirine failure among ARV-naive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2983-2987.	3.0	14
7	Usefulness of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) DNA Viral Load in Whole Blood for Diagnosis and Monitoring of KSHV-Associated Diseases. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	11
8	Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 196-204.	3.0	11
9	Current and Future Tools for Diagnosis of Kaposi's Sarcoma. <i>Cancers</i> , 2021, 13, 5927.	3.7	11
10	Plasma cystatin C as a marker for estimated glomerular filtration rate assessment in HIV-1-infected patients treated with dolutegravir-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1935-1939.	3.0	8
11	Poppers, by Inducing HHV-8 Virion Production, Can Act as a Promoter for HHV-8 Transmission in Men Who Have Sex With Men. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab166.	0.9	8
12	Efficacy of intermittent short cycles of integrase inhibitor-based maintenance ART in virologically suppressed HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1321-1323.	3.0	7
13	Kaposi's Sarcoma in Virally Suppressed People Living with HIV: An Emerging Condition. <i>Cancers</i> , 2021, 13, 5702.	3.7	7
14	Initial Failure of Pristinamycin Treatment in a Case of Multidrug-Resistant <i>Mycoplasma genitalium</i> Urethritis Eventually Treated by Sequential Therapy. <i>Sexually Transmitted Diseases</i> , 2021, 48, e163-e164.	1.7	5
15	Household transmission of SARS-CoV-2 infection in the Paris/Ile-de-France area. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 445-454.	2.9	5
16	Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma. <i>Cancers</i> , 2022, 14, 484.	3.7	5
17	Immune Reconstitution Inflammatory Syndrome Associated Kaposi Sarcoma. <i>Cancers</i> , 2022, 14, 986.	3.7	5
18	Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2022, 225, 502-509.	4.0	4

#	ARTICLE	IF	CITATIONS
19	The Role of Radiotherapy in Treating Kaposi's Sarcoma in HIV Infected Patients. <i>Cancers</i> , 2022, 14, 1915.	3.7	4
20	Presence of HIV-1 G-to-A mutations linked to APOBEC editing is more prevalent in non-B HIV-1 subtypes and is associated with lower HIV-1 reservoir. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2148-2152.	3.0	3
21	No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1573-1579.	3.0	2
22	No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1553-1557.	3.0	1
23	Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1893-1897.	3.0	1
24	No increased risk of Kaposi sarcoma relapse in patients with controlled HIV-1 infection after switching protease inhibitor-based antiretroviral therapy. <i>HIV Medicine</i> , 2022, 23, 301-306.	2.2	1
25	Distribution of HIV self-tests by men who have sex with men attending a French sexual health centre: results of the OTO study. <i>Sexually Transmitted Infections</i> , 2022, , sextrans-2022-055417.	1.9	1
26	Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 477-481.	3.0	0
27	More HIV-1 RNA detected and quantified with the Cobas 6800 system in patients on antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 0, , .	3.0	0